New cell prep method aims to tame transplant complications in kids
NCT ID NCT06393660
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study offers a special way to prepare donor stem cells for children and teens under 22 who need a transplant but lack a perfectly matched sibling donor. The method uses the CliniMACS® system to remove certain immune cells, which may help reduce the risk of graft-versus-host disease (a serious complication where donor cells attack the patient's body). The goal is to make the transplant safer and more effective for controlling transplant-related disorders.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
Up to 21 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Recipient Inclusion Criteria: * Age less than 22 years of age * No available genotypically matched related donor (sibling) * Availability of a suitable donor and graft source * Haploidentical related mobilized peripheral blood cells * 9/10 or 10/10 allele matched (HLA-A, -B, -C, -DRB1, -DQB1) volunteer unrelated donor mobilized peripheral blood cells Donor Inclusion Criteria: * Matching as described in the Recipient and Donor Suitability Criteria * Size and vascular access appropriate by center standard for peripheral blood stem cell (PBSC) collection. Donors with inadequate peripheral access will require placement of an apheresis catheter for collection. * Must meet appropriate screening/eligibility requirements: * Haploidentical matched family members: screened by center health screens and found to be eligible. * Unrelated donors: meet suitability criteria to donate PBSC * HIV negative * Not pregnant or lactating * Recipient must not have high-level donor specific anti-HLA antibodies according to institutional practices. * Must agree to donate PBSC * Must give informed consent Recipient Suitability: \- Adequate organ functioning as demonstrated by: * MUGA ≥ 50% or ECHO \>30% * 24-hour Creatinine Clearance or Glofil ≥ 50 ml/min or Serum Creatinine ≤2 times the upper limit of normal * DLCO \> 65% of predicted value. FEV1 \>65% of predicted * AST / ALT ≤ 2.5 and/or Bilirubin ≤ 1.5 times the upper limit of normal * Pregnancy test negative * HIV 1 / 2 (HIV screen) negative with a negative qualitative HIV PCR. * HTLV I negative * RPR or VDRL negative * RVP (Respiratory Viral PCR) with a negative result * Positive hepatitis testing does not make the patient ineligible. Hepatitis results will be evaluated on a case-by-case basis by the transplant physician to determine donor suitability/eligibility. Donor Suitability: \- Allowed Donor Sources * Fully matched sibling donors are not allowed. * Unrelated donors. HLA typing of at least 10 alleles is required. Donor must be matched at 9/10 or 10/10 alleles (HLA-A, -B, -C, -DRB1, -DQB1). Haploidentical matched family members. Minimum match level full haploidentical (at least 5/10; HLA-A, -B, -C, -DRB1, -DQB1 alleles), but use of haploidentical donors with extra matches (e.g., 6, 7, or 8/10) encouraged. * Cord blood is not allowed as a stem cell source on this IDE. Recipient and Donor Exclusion Criteria: * Pregnant or lactating females are ineligible as the risk to unborn children and infants is unknown * Presence of life-threatening, uncontrolled opportunistic infection (fungal, bacterial, or viral infections). Patients with history of fungal disease during induction therapy may proceed if they have a significant response to antifungal therapy with no or minimal evidence of disease remaining by CT evaluation. * HIV or HTLV I/II infection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GVH - graft versus host reaction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Children's Medical Center - Dallas
AVAILABLEDallas, Texas, 75235, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding methotrexate to steroids tame a dangerous transplant complication?
- New bedside test may cut blood transfusions in lung transplants
- New hope for transplant patients: easier CMV prevention on the horizon?
- New model may predict and prevent deadly transplant complication
- Can we predict diabetes after a liver transplant?
- Nerve check may predict transplant complication risk